Polyphor AG

  • ISIN: CH0106213793
  • Land: Schweiz

Nachricht vom 11.09.2020 | 18:50

Polyphor to present at the H.C. Wainwright Global Investment Conference

Polyphor AG / Key word(s): Conference

11-Sep-2020 / 18:50 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.


Allschwil, Switzerland, September 11, 2020

Polyphor to present at the H.C. Wainwright Global Investment Conference

Polyphor AG (SIX: POLN) today announced that the company will present at the 22st Annual H.C. Wainwright Global Investment Conference, taking place September 14 -16, 2020 (Virtual Conference). Gokhan Batur, CEO of Polyphor, will provide an overview of the company and its pipeline and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. A replay of the webcast will be available for 90 days following the conclusion of the event.

Presentation details:
Date: Tuesday September 15, 2020
Time: 02:00pm EDT
Online Registration: www.hcwevents.com

For further information please contact:

For Investors:
Hernan Levett
Chief Financial Officer
Polyphor Ltd.
Tel: +41 61 567 16 00
Email: IR@polyphor.com

For Media:
Stephan Feldhaus
Feldhaus & Partner GmbH
Tel: +41 79 865 92 56
Email: feldhaus@feldhaus-partner.ch

About Polyphor
Polyphor is a research-driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing first-in-class molecules in oncology and antimicrobial resistance leveraging the company's leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company's lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.

Disclaimer
This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor's results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.



End of ad hoc announcement

show this

GBC-Fokusbox

Northern Data: "Waren zum richtigen Zeitpunkt mit dem richtigen Konzept am Markt"

Kryptowährungen, allen voran Bitcoin, sind zuletzt mit deutlichen Steigerungen wieder in den Investorenfokus gerückt. Northern Data, ein Spezialist für High Performance Computing, zählt laut eigenen Angaben zu den weltweit führenden Anbietern für Infrastruktur im Bereich Bitcoin-Mining. Wir haben mit dem Gründer und CEO Aroosh Thillainathan über die Perspektiven für Bitcoin und die Wachstumsaussichten für die Northern Data gesprochen.

News im Fokus

Merck KGaA: Merck KGaA bricht klinische Studie für bintrafusp alfa (INTR@PID Lung 037) ab

20. Januar 2021, 13:30

Aktuelle Research-Studie

HELMA Eigenheimbau AG

Original-Research: HELMA Eigenheimbau AG (von GBC AG): Kaufen

21. Januar 2021